Oppenheimer Starts Calpine (CPN), Centerpoint (CNP) at Outperform, Sempra (SRE) at Perform
Tweet Send to a FriendGet Alerts CPN Hot Sheet
Price: $21.33 +1.67%
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade CPN Now!
In the after-hours session today, Oppenheimer has initiated coverage on several stocks related to the Natural Gas sector.
The firm started shares of Calpine (NYSE: CPN) and Centerpoint Energy (NYSE: CNP) at Outperform and shares of Sempra Energy (NYSE: SRE) at Perform.
Oppenheimer set a $16 price target on Calpine shares, an $18 target on Centerpoint, and a $56 price target on shares of Sempra.
Check out our Ratings Central portal to get the most comprehensive and up-to-date analyst coverage on the Street.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm started shares of Calpine (NYSE: CPN) and Centerpoint Energy (NYSE: CNP) at Outperform and shares of Sempra Energy (NYSE: SRE) at Perform.
Oppenheimer set a $16 price target on Calpine shares, an $18 target on Centerpoint, and a $56 price target on shares of Sempra.
Check out our Ratings Central portal to get the most comprehensive and up-to-date analyst coverage on the Street.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- UBS Starts Regeneron Pharma (REGN) at Neutral
- Needham & Company Starts Infoblox (BLOX) at Buy; Margin Expansion Story
Create E-mail Alert Related Categories
New CoverageLogin with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

